NCT02890758 2023-02-21Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803Case Comprehensive Cancer CenterPhase 1 Completed14 enrolled
NCT03003728 2020-07-102015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)University of ArkansasPhase 2 Withdrawn